Lilak, Takeda Pharmaceutical, Actos & Bladder Cancer: A recent case in the United States District Court, D. Colorado ruled on motion for summary judgment. The Lilak, Takeda Pharmaceutical, Actos & Bladder Cancer case documents what many actos prescription drug users may face today – potential bladder cancer. The court ruled on the motion.
A brief summary of the facts include:
- The background facts have been set forth elsewhere and will not be restated here except as relevant to resolving the Objection. See Docket No. 65 at 1-6. Plaintiff brings a products liability action against defendant, claiming that the drug Actos and related drugs caused plaintiff a variety of injuries. In its motion for summary judgment, defendant provided a declaration from Dr. Mark Molitch, who stated that, based on his review of plaintiff’s medical records, plaintiff has never suffered from urinary tract infections (“UTIs”) or bladder cancer and that the other conditions plaintiff complains of were not caused by Actos.
To find out more on the case, see Case No. 11-cv-03379-PAB-MJW – January 6, 2015.
Actos is sold under the brand-name Actos ((pioglitazone) class of drugs which help to lower blood glucosue levels), may be sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride (Duetact) and may be used along with diet and exercise to improve control of blood sugar in adults with type 2 diabetes mellitus.
We are currently investigating claims involving the development of bladder cancer arising from the use of Actos and can help you file an actos lawsuit.
For more information on actos and bladder cancer, click here.
At the Gooch Law Firm, we pride ourselves on providing our clients reliable representation for even the most challenging cases. If you or a loved one have taken Actos and are now suffering from side effects related to Actos (e.g., bladder cancer) and would like your case evaluated, contact our office at 1.844.329.5955.
WE ARE HERE TO HELP YOU PROTECT YOUR LEGAL RIGHTS